SAB Biotherapeutics (SABS) Operating Leases (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Operating Leases data on file, last reported at $2.2 million in Q1 2026.

• Quarterly Operating Leases fell 12.01% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 12.01% YoY) and the FY2025 annual result came in at $1.9 million, up 223.04% from the prior year.
• Operating Leases grew to $2.2 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.5 million in Q1 2025 to a low of $227652.0 in Q1 2023.
• A 5-year average of $1.2 million and a median of $772605.0 in 2022 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases plunged 87.08% — and 2025, when it surged 344.91%.
• Tracing SABS's Operating Leases over 5 years: stood at $361225.0 in 2022, then jumped by 76.01% to $635777.0 in 2023, then fell by 8.59% to $581148.0 in 2024, then jumped by 223.04% to $1.9 million in 2025, then increased by 15.64% to $2.2 million in 2026.
• The last three Operating Leases figures came in at $2.2 million (Q1 2026), $1.9 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.